Sebaceous hyperplasia

[1]

Overview & Definition

Sebaceous hyperplasia (SH) is a common, benign, hamartomatous proliferation of mature sebaceous glands that presents as one or more small (2–9 mm), soft, yellowish-to-skin-coloured papules, each with a characteristic central dell (umbilication), on the sun-exposed skin of the face of middle-aged and older adults. It is the most common benign tumour of the sebaceous gland and is essentially harmless, although it may be cosmetically bothersome and is the most frequent clinical mimic of nodular basal cell carcinoma (BCC).[1][3]

The histological hallmark is enlarged but cytologically mature sebaceous lobules arranged radially around a central dilated duct that opens onto the skin surface — the structural correlate of the clinical central dell. Because the sebocytes retain a mature, differentiated, polyclonal phenotype with no atypia, SH is classified as a hyperplasia (a reversible, reactive increase in cell number within a normally structured tissue) rather than a neoplasm (a monoclonal proliferative lesion such as sebaceous adenoma, sebaceoma or sebaceous carcinoma).[6]

The condition is also termed senile sebaceous hyperplasia or Jadassohn-type sebaceous hyperplasia (after Josef Jadassohn, who described the entity in the late nineteenth century). It is distinct from Fordyce spots (ectopic free sebaceous glands on the oral mucosa, lips, buccal mucosa and genitalia — a normal anatomical variant) and from Montgomery tubercles (areolar sebaceous glands). SH has no malignant potential itself, but its presence — particularly when multiple, premature, or histologically atypical — can be a cutaneous sentinel for systemic disease, most importantly Muir-Torre syndrome (a phenotypic variant of Lynch syndrome).[6][7]

Classification

SH is classified by morphology, age of onset, and pattern of distribution:[1]

1. Classic / senile / Jadassohn-type SH — the common form; one or more 2–9 mm yellow papules on the face of adults aged ≥ 50 (peak 60–80). Histologically, ≥ 50 % mature sebocytes with one to several enlarged lobules surrounding a dilated central duct. [1]

2. Premature SH — identical morphology but appearing before age 40; usually familial with autosomal dominant inheritance. Should prompt a careful family history and consideration of associated lipid or androgen abnormalities. [1]

3. Linear / naevoid SH — lesions arranged along Blaschko's lines, often unilateral; considered a mosaic disorder of the pilosebaceous unit. [1]

4. Giant SH — unusually large lesion ≥ 10 mm (occasionally several centimetres) mimicking a BCC or other adnexal tumour; biopsy mandatory. [1]

5. Diffuse / eruptive / disseminated SH — sudden appearance of numerous lesions, classically in the setting of immunosuppression (solid-organ transplant recipients on cyclosporin A, HIV/AIDS) or, rarely, secondary to cyclosporin, sirolimus, or other drugs.[8]

6. Bullous SH — a rare variant in which bullae form overlying a confluent plaque of SH, often on the dorsum of the hand; believed to reflect dermal lymphatic obstruction by the hyperplastic glands. [1]

A second, complementary axis classifies sebaceous tumours along a benign-to-malignant spectrum that the clinician must always bear in mind when evaluating a yellow papule on the face:[6]

The cardinal lesson: any single rapidly growing, ulcerated, or atypical yellow facial papule, and any multiple or extracellular sebaceous tumour, must be biopsied. [1]

Epidemiology & Risk Factors

[1]

Age and sex. Classic SH is overwhelmingly a disorder of older adults; onset before age 40 is unusual and should raise the question of familial premature SH, immunosuppression, or an underlying iatrogenic trigger. Men are affected roughly twice as often as women, attributed in part to the lifelong androgenic stimulation of the male pilosebaceous unit (men have larger sebaceous glands and higher sebum secretion through adulthood).[1]

Skin type and sun exposure. Lesions favour fair-skinned individuals and arise almost exclusively on chronically sun-exposed skin (face, forehead, nose, cheeks, bald scalp). Cumulative ultraviolet damage is believed to alter the dermal connective-tissue scaffold supporting the pilosebaceous unit, contributing to ductal dilation and glandular proliferation.[1]

Solid-organ transplantation and cyclosporin. SH appears prematurely and with markedly increased frequency (reported in 10–30 %) in recipients of kidney, heart and liver transplants maintained on cyclosporin A (a calcineurin inhibitor). Cyclosporin has direct trophic effects on the sebaceous gland (sebocyte proliferation, altered sebum composition) and may also act via immunomodulation of perifollicular T-cell cytokines. The effect appears partly drug-specific — switching to tacrolimus has been reported in small series to reduce eruptive SH.[8]

Other systemic associations. Rare associations include HIV/AIDS (where SH must be distinguished from the many other causes of facial papules, particularly molluscum contagiosum and eosinophilic folliculitis), chronic hepatitis C, diabetes mellitus, and hyperlipidaemia, although these last two are confounded by age and shared vascular risk factors. [1]

Genetics. The rare familial premature form is autosomal dominant. Muir-Torre syndrome — see Special Populations — is the key inherited association and is autosomal dominant due to germline mismatch-repair gene mutations.[6][7]

Pathophysiology

[1]

The pathogenesis is best understood as the convergence of three mechanisms: [1]

1. The age-related androgen hypothesis. Sebaceous glands are androgen-responsive organs; their activity is driven by dihydrotestosterone (DHT), generated locally from testosterone by 5α-reductase in the sebocyte basal layer. Androgens maintain both the size of the gland and the rate of sebocyte lipid synthesis. With ageing, circulating androgen levels decline (the adrenopause and gonadopause of late middle age), and one might naïvely expect glandular atrophy. Instead, in SH, individual pilosebaceous units develop a selective, paradoxical hypersensitivity of the androgen receptor and/or an altered 5α-reductase activity, so that even reduced androgenic tone drives focal glandular enlargement. The result is a small number of markedly enlarged but otherwise normal-structured glands sitting in elderly skin. [1]

2. The ductal-obstruction / retention sequence. The central sebaceous duct drains to the surface through a narrow infundibulum. Age-related loss of dermal collagen and elastin (chronic heliodermatitis) reduces perifollicular support, the duct wall weakens, and retained sebum progressively dilates the duct. The visible central dell corresponds to the open mouth of this dilated duct. Surrounding sebaceous lobules enlarge in parallel, presumably in response to trophic signalling from the dilated duct and ongoing androgen drive. The yellow clinical colour reflects the lipid-rich mature sebocytes visible through the thin overlying epidermis. [1]

3. The iatrogenic / immunological driver (transplant and HIV settings). In cyclosporin-associated eruptive SH, the drug appears to act directly on the sebocyte: in vitro cyclosporin stimulates sebocyte proliferation and lipid synthesis through calcineurin / NFAT-dependent pathways, and indirectly alters the perifollicular cytokine milieu. The result is widespread, multifocal, premature SH in a young immunosuppressed patient. An analogous driver may operate in HIV, where immune dysregulation, cytokine shift, and antiretroviral drug effects each contribute. [1]

Why hyperplasia and not neoplasia? Histology of SH shows a polyclonal expansion of mature sebocytes with preserved lobular architecture; there is no atypia, no infiltrative growth and no destructive invasion — the structural definition of hyperplasia. This is the histological and biological distinction from sebaceous adenoma, sebaceoma and sebaceous carcinoma, which are clonal neoplasms. SH itself does not transform into sebaceous carcinoma.[6]

Why the face? The density of sebaceous glands is greatest on the face (forehead, nose, cheeks — the so-called T-zone, where there may be 400–900 glands per cm², compared with ~ 50 per cm² elsewhere), and these glands are the largest and most androgen-responsive in the body. Combined with chronic sun exposure, this anatomical concentration explains the characteristic distribution. [1]

Clinical Presentation

Classical morphology. A typical lesion is a 2–9 mm, soft, doughy, skin-coloured-to-yellow papule with a discrete central dell or umbilication measuring ~ 1 mm. Gentle lateral pressure may express a tiny droplet of sebum from the central pore. The lesion is non-tender and asymptomatic; the patient is bothered only by the cosmetic appearance. Lesions may be single or multiple (commonly 2–10), and individual lesions are stable in size over months to years once established.[1]

Distribution. The classic sites, in order of frequency, are: forehead, nose (especially the ala), cheeks, and nasolabial folds. Less commonly involved are the bald scalp, temples, chin, upper chest, upper back, areola, and scrotum — sites that all share a high density of sebaceous glands. Oral mucosal involvement does not occur (Fordyce spots are a separate entity). [1]

Number and arrangement. Most patients have a few discrete lesions; some have clusters on the forehead or cheeks; rarely the eruptive / disseminated form produces dozens to hundreds of lesions in an immunosuppressed patient. Lesions are usually discrete but can coalesce into plaque-like or, very rarely, giant (≥ 10 mm) or bullous forms. [1]

Atypical presentations. [1]

• Giant SH (≥ 10 mm) mimics BCC or adnexal tumour and mandates biopsy.
• Eruptive / diffuse SH in transplant recipients or HIV — hundreds of lesions over weeks to months.[8]
• Premature / familial SH in adolescence or young adulthood (autosomal dominant).
• Linear / naevoid SH following Blaschko's lines.
• SH of the areola or scrotum — easily mistaken for ectopic glands or warts.

Symptoms. Classically absent; occasional mild pruritus or cosmetic concern. Pain, bleeding, rapid growth, ulceration or colour change are not features of SH and demand biopsy to exclude BCC or sebaceous carcinoma. [1]

Natural history. Lesions appear insidiously in middle age, multiply slowly over years, and persist indefinitely without spontaneous resolution. They are not pre-malignant and do not regress. [1]

Differential Diagnosis

The two clinical questions an examiner always returns to are: (i) "Is this a benign sebaceous lesion or a BCC?" and (ii) "Could this be a sentinel lesion of Muir-Torre syndrome?" The complete differential: [1]

[1]

The single must-not-miss diagnosis is nodular BCC. Both SH and nodular BCC are pearly / yellow papules on the sun-exposed face of older adults. Three reliable discriminators: [1]

1. Vessels. SH has delicate crown vessels arranged in a ring at the periphery that do not cross the central dell; BCC has arborising (branching, tree-like) telangiectatic vessels that traverse the lesion and often cross the centre.[3][4]
2. Surface. SH retains a smooth, umbilicated surface; BCC frequently shows rolling translucent border, central depression / ulceration (rodent ulcer), and may bleed with minor trauma.
3. Behaviour. SH is stable for years; BCC enlarges slowly and progressively, develops ulceration, and may bleed.

Any single lesion with red-flag features (growth, ulceration, bleeding, colour change, ≥ 10 mm) must be biopsied.[6]

Clinical & Bedside Assessment

A focused dermatological assessment of a suspected SH should answer three questions in turn: (1) Is this clinically typical? (2) Does dermoscopy confirm SH? (3) Are there features triggering biopsy or systemic workup? [1]

1. Lighting, magnification, dermoscopy. Examine the patient in good room light with tangential (side) lighting to highlight the central dell and the yellow colour. A hand-held magnifier or dermatoscope (with a drop of ultrasound gel) reveals the pathognomonic crown vessels, yellow lobules, and central umbilication. [1]

2. The central dell sign. Gentle lateral pressure on the lesion may express a tiny droplet of sebum from the dilated central duct. This sign is supportive but not diagnostic (milia, molluscum and small BCCs do not show it). [1]

3. Distribution and number. Examine all of the sebaceous-rich sites (forehead, cheeks, nose, nasolabial folds, bald scalp, chest, upper back). Document the number, size, and distribution of lesions. Multiple lesions favour SH; a single lesion in an otherwise clear area warrants a higher index of suspicion for BCC. [1]

4. Red-flag features. Carefully document any of: rapid growth, change in colour (red, brown, black, blue-grey), ulceration, bleeding, induration, fixation to deeper tissue, ≥ 10 mm size, satellite lesions, regional lymphadenopathy. Each mandates biopsy. [1]

5. Systemic and family history (Muir-Torre screening). Take a three-generation family history of colorectal, endometrial, urothelial, gastric, ovarian, and sebaceous skin cancers. Ask about the patient's own history of colonic polyps, bowel resection, abnormal colonoscopy, or visceral malignancy. A personal or family history of any Lynch-spectrum cancer in a patient with one or more sebaceous tumours raises Muir-Torre syndrome.[6][7]

6. Drug history. Specifically ask about cyclosporin, tacrolimus, sirolimus, lithium, testosterone replacement / anabolic steroids, phenytoin, and any prior transplant or chronic immunosuppression. [1]

7. Examine ectopic / extra-facial sites. Inspect the oral mucosa (Fordyce spots — normal variant), areolae (Montgomery tubercles), scrotum, and eyelids. A yellowish nodule on the eyelid in an older adult should prompt consideration of sebaceous carcinoma, which carries high metastatic potential and requires urgent biopsy. [1]

Investigations

SH is a clinical diagnosis confirmed by dermoscopy in the typical setting. Biopsy is reserved for atypical, enlarging, ulcerated or treatment-resistant lesions, and for any lesion where BCC or sebaceous carcinoma cannot be confidently excluded.[1]

Dermoscopy — the pathognomonic triad.[3][4][5]

• Crown vessels — delicate, arborising-to-linear telangiectatic vessels arranged in a ring around the periphery of the lesion, extending toward but NOT crossing the centre. The crown pattern is highly specific for SH; in BCC the equivalent vessels cross the centre of the lesion.
• Yellow-white globules / cumulus sign — multiple yellow-white lobular structures representing the hyperplastic mature sebaceous lobules seen through the thin epidermis; the appearance resembles cumulus clouds.
• Central umbilication / bonbon toffee sign — a central depression / crater corresponding to the dilated duct opening, surrounded by the cumulus sign. Oztas et al. coined the term bonbon toffee sign because the appearance resembles a hard toffee with a central indent.[5]

Histopathology (when biopsy performed). [1]

• Enlarged, mature sebaceous lobules (often one to several) arranged radially around a central dilated duct opening to the surface.
• The sebocytes are mature — large, polygonal cells with clear vacuolated lipid-rich cytoplasm and a small central scalloped nucleus.
• A thin rim of basaloid germinative cells (one to two layers) lies at the periphery of each lobule; the ratio of mature sebocytes to basaloid cells is > 50 % mature, which distinguishes SH from sebaceous adenoma (~ 50 : 50) and sebaceoma (> 50 % basaloid).[6]
• No cellular atypia, no mitoses, no infiltrative growth, no perineural or lymphovascular invasion.

Immunohistochemistry for mismatch repair (MMR) proteins. Any biopsy that proves to be a sebaceous adenoma, sebaceoma, or sebaceous carcinoma (and many authorities advocate: any sebaceous tumour at all) should undergo MMR IHC for the four proteins — MLH1, MSH2, MSH6, PMS2.[6][7]

• Loss of MSH2 (with secondary loss of MSH6) is the most common pattern in Muir-Torre syndrome, accounting for ~ 80–90 % of cases.
• Loss of MLH1 (with secondary loss of PMS2) accounts for most of the remainder; isolated loss of PMS2 or MSH6 occurs in a minority.
• MMR IHC is screening, not diagnostic. False negatives occur, so high clinical suspicion warrants germline testing regardless of IHC. [1]

Muir-Torre / Lynch workup (when a sentinel sebaceous tumour is identified).[6][7]

• Germline genetic testing for MLH1, MSH2, MSH6, PMS2 (and EPCAM, which deletes the upstream promoter of MSH2).
• Colonoscopy — full colonoscopy with biopsies.
• Upper endoscopy if upper-GI cancer in family.
• Pelvic imaging / endometrial sampling in women.
• Urinalysis / cystoscopy / upper-tract imaging for urothelial cancer.
• Family cascade screening once a pathogenic variant is found.
• A clinical scoring system (Roberts et al., PMID 24603434) uses age at first sebaceous tumour, number of sebaceous tumours, and personal / family history of Lynch-spectrum visceral cancer to stratify which patients most warrant germline testing.[7]

Reflectance confocal microscopy (RCM). A non-invasive bedside technique that can show the enlarged sebaceous lobules with bright refractile lipid-laden sebocytes and the dilated central duct — useful in specialist units to avoid biopsy of typical lesions. [1]

No blood tests are required for typical SH. In the premature / familial form, consider fasting lipids, lipid profile, and (in selected cases) serum androgens, but these are not routine. [1]

Management — Resuscitation

SH is never a dermatological emergency. There is no acute resuscitative phase. The 'urgency' in suspected SH sits entirely with the conditions that mimic it: [1]

• Suspected BCC with rapidly enlarging, ulcerating or bleeding facial lesion — urgent (2-week-wait) dermatology referral and diagnostic biopsy within 2–4 weeks.
• Suspected sebaceous carcinoma (eyelid yellowish nodule, rapidly growing, ulcerating, fixed) — urgent ophthalmology / oculoplastic / dermatology referral; biopsy is time-critical because pagetoid conjunctival spread and orbital invasion may occur.
• Multiple sebaceous tumours with visceral cancer history — Muir-Torre workup should be initiated promptly (within weeks) to enable early detection of colorectal or other visceral malignancy. [1]

For typical, asymptomatic SH, reassurance and counselling about the benign nature and the timeframe of cosmetic treatment is the most important 'first step'. No treatment is mandatory. [1]

Management — Definitive & Stepwise

Step 0 — Conservative / reassurance

• Confirm diagnosis clinically + dermoscopically.
• Counsel that SH is benign, non-premalignant, and cosmetic only.
• Sun protection (broad-spectrum SPF 30+ daily) — may slow new lesion formation in chronically exposed skin.
• No treatment is a legitimate option for the asymptomatic patient. [1]

Step 1 — First-line destructive modalities

Step 2 — Laser modalities

Laser ablation is preferred when the patient has multiple facial lesions where scarring must be minimised.[2]

• Ablative CO₂ laser (10 600 nm) — vaporises the lesion; 1–2 passes; ~ 70–90 % clearance; ~ 1-week downtime; small risk of scarring and post-inflammatory pigment change.
• Erbium:YAG (Er:YAG) (2940 nm) — more tissue-selective (high water absorption), finer ablation, less thermal damage, faster healing, very suitable for facial SH; excellent cosmetic outcome.[2]
• Pulsed-dye laser (PDL) (585 / 595 nm) — targets the vascular crown vessels; useful as monotherapy for small lesions or as an adjunct to reduce erythema after ablation.
• KTP / 532 nm — also targets the vascular component.
• Alexandrite / Nd:YAG (1064 nm) — used in some units for darker phototypes.

Step 3 — Photodynamic therapy (PDT)

• Topical 5-aminolaevulinic acid (ALA) or methyl aminolaevulinate (MAL), incubation 1–3 h, illumination with red light (630 nm) or intense pulsed light.
• Useful for multiple lesions or field treatment of actinic damage.
• 1–3 sessions at 4-week intervals; ~ 60–80 % clearance. [1]

Step 4 — Oral isotretinoin for extensive / eruptive disease

For diffuse or eruptive SH (transplant recipients, HIV, multiple lesions unresponsive to local therapy), systemic retinoid therapy suppresses sebocyte activity and shrinks lesions:[1][8]

• Agent / dose / route — oral isotretinoin 0.5 mg/kg/day (range 0.25–1.0 mg/kg/day) PO with food, for 2–6 weeks, then a maintenance dose of 0.25–0.5 mg/kg/day for 2–6 months.
• Mechanism — potent, direct suppression of sebaceous gland size, sebum output and sebocyte proliferation.
• Efficacy — high initial response, but recurrence is the rule after discontinuation, often within weeks to months. Many patients require repeated courses or low-dose long-term maintenance.
• Pre-treatment workup — fasting lipids, liver function tests, serum β-hCG (pregnancy test) in women of childbearing potential, full blood count.
• Monitoring — lipids and LFTs at 1 month then 3-monthly; pregnancy test monthly during therapy and for 1 month after (highly teratogenic — iPLEDGE / PPP).
• Contraindications — pregnancy, breastfeeding, uncontrolled hyperlipidaemia, significant hepatic impairment, concurrent tetracyclines (raises intracranial pressure).
• In transplant recipients — use is off-licence and specialist-only; isotretinoin has been reported to be effective for cyclosporin-induced eruptive SH but interacts with immunosuppression (caution with azole antifungals and macrolides via CYP3A4) and may affect renal function in this setting.[8]

Step 5 — Adjunctive / emerging

• Topical retinoids (tretinoin 0.025–0.1 %, adapalene 0.1 %) nightly — palliative; may reduce lesion prominence but does not eliminate established lesions.
• Topical bimatoprost 0.03 % — reported in small series to reduce lesion size (mechanism unclear; prostaglandin effect on sebocytes).
• Intralesional botulinum toxin — anecdotal.
• Switching cyclosporin to tacrolimus in transplant patients with eruptive SH — may reduce new lesion formation.[8]

Stepwise approach to failure

1. Typical solitary lesion → cryotherapy or ED&C.
2. Multiple facial lesions → Er:YAG or CO₂ laser; consider PDT for field change.
3. Diffuse / eruptive / transplant-related → oral isotretinoin (specialist).
4. Atypical / enlarging / ulcerated lesion → biopsy first, treat the diagnosis. [1]

Specific Subtypes & Scenarios

• Classic senile SH in a fit elderly patient — single session cryotherapy or laser; sun protection; annual review for new lesions and skin-cancer surveillance (these patients are at high background risk of BCC, SCC and melanoma).
• Premature familial SH — screen first-degree relatives; consider lipid and androgen workup; treatment is cosmetic as above; counsel about autosomal dominant inheritance.
• Giant SH — biopsy to exclude adnexal tumour; surgical excision or CO₂ laser ablation.
• Linear / naevoid SH — cosmetic laser or excision of individual lesions; no systemic therapy.
• Eruptive SH in renal transplant on cyclosporin — switch to tacrolimus where feasible; oral isotretinoin (specialist supervision); laser or PDT for individual lesions.[8]
• SH in HIV / AIDS — exclude molluscum contagiosum (which is often co-existing); ART optimisation; isotretinoin or laser for extensive disease.
• A biopsy that returns sebaceous adenoma / sebaceoma — Muir-Torre workup (see Investigations).
• SH in a woman of childbearing potential requiring isotretinoin — full contraception / iPLEDGE-PPP-compliant counselling, monthly pregnancy testing, informed consent.

Complications & Pitfalls

Complications of the disease itself are essentially nil — cosmetic concern only. SH does not transform into sebaceous carcinoma and does not metastasise. [1]

Complications of treatment include: [1]

• Scarring (especially after ED&C and deep CO₂ laser).
• Post-inflammatory hyperpigmentation (PIH) — a major concern in Fitzpatrick IV–VI skin; avoid cryotherapy in dark phototypes.
• Hypopigmentation — cryotherapy is the principal offender (melanocytes are more cold-sensitive than keratinocytes).
• Recurrence — common after all modalities; the underlying glandular hyperplasia can re-form.
• Infection / bleeding — rare with proper aseptic technique.
• Isotretinoin adverse effects — teratogenicity, mucocutaneous dryness, cheilitis, xerosis, epistaxis, photosensitivity, transaminitis, hypertriglyceridaemia, mood change (controversial), benign intracranial hypertension (especially with tetracyclines), premature epiphyseal closure in children. [1]

Critical pitfalls. [1]

1. Misdiagnosis of nodular BCC as SH. Both are pearly papules on the sun-exposed face of older adults; failure to biopsy a changing or atypical lesion delays cancer diagnosis.
2. Missing sebaceous carcinoma. Especially on the eyelid — a yellowish nodule that grows, ulcerates, or bleeds requires urgent biopsy; pagetoid conjunctival spread and orbital invasion can be vision- and life-threatening.
3. Overlooking Muir-Torre syndrome. Multiple or histologically atypical sebaceous tumours should trigger MMR IHC and Lynch workup; missing the diagnosis delays detection of colorectal, endometrial and urothelial cancers.
4. Treating the lesion without addressing the trigger. In cyclosporin-induced eruptive SH, treating individual lesions without discussing calcineurin-inhibitor switch with the transplant team guarantees recurrence.
5. Aggressive over-treatment. Treating dozens of lesions in a single session (cumulative downtime, scarring, pigment change) rather than staged sessions over weeks.
6. Using isotretinoin in pregnancy or without contraception — catastrophic teratogenicity. [1]

Prognosis & Disposition

• Natural history — chronic, slowly progressive, no spontaneous resolution; lesions stable once established.
• Malignant transformation — does not occur; SH is not a precursor of sebaceous carcinoma.[6]
• Recurrence after treatment — common after cryotherapy, ED&C, laser and even oral isotretinoin; patients should be forewarned that maintenance or repeat treatment is often required.
• Muir-Torre prognosis — when a cutaneous sebaceous tumour is the sentinel presentation of Muir-Torre syndrome, early diagnosis and initiation of cancer surveillance (colonoscopy, endometrial sampling, urothelial surveillance) improves visceral cancer outcomes; the sebaceous lesion itself is often cured by excision.
• Disposition — typical SH is managed in primary care or dermatology outpatient clinic; atypical / changing lesions, suspected sebaceous carcinoma, and Muir-Torre workup require specialist (often multidisciplinary) referral.

Special Populations

Evidence, Guidelines & Regional Differences

• Zaballos et al. (2005, PMID 15967945) — the seminal dermoscopy paper establishing crown vessels as a specific feature of SH and their distinction from the arborising vessels of BCC.[3]
• Argenziano et al. (2004, PMID 15611426) — the larger dermoscopy study of vascular structures in non-melanocytic skin tumours, providing the framework for distinguishing BCC, SH, and other clear-cell tumours by vessel morphology.[4]
• Oztas et al. (2008, PMID 18540985) — coined the bonbon toffee sign (central umbilication surrounded by the cumulus sign) and reported it in 80 % of SH cases.[5]
• Liu et al. (2020, PMID 32484621) — review of laser modalities and case series of Er:YAG for SH, demonstrating high clearance (~ 75–95 %) with minimal scarring.[2]
• Hussein / Perrett (2021, PMID 32011918) — comprehensive review of treatment literature, concluding that no single modality is clearly superior, that recurrence is common across modalities, and that isotretinoin is reserved for extensive / eruptive disease.[1]
• Aksoy et al. (2020, PMID 33381706) — case report of successful systemic isotretinoin for cyclosporin-induced eruptive SH in a renal transplant recipient, illustrating the off-licence specialist role.[8]
• Roberts et al. (2014, PMID 24603434) — the clinical scoring system for stratifying which patients with sebaceous neoplasms warrant germline Lynch testing.[7]
• Shalin et al. (2014, PMID 25427047) — pathology review of Muir-Torre syndrome, defining the histological spectrum, MMR-IHC patterns, and clinical criteria.[6]

Regional differences. Most major guidelines (AAD US, BAD UK, EADV Europe, IADVL India) converge on the same principles: SH is benign, treatment is cosmetic, and atypical / multiple sebaceous tumours warrant Muir-Torre screening. Practical differences include: isotretinoin availability (generic widely available in India, brand-restricted in some markets with strict iPLEDGE / PPP requirements in the US and UK); PDT access (variable, often specialist-only); and the threshold for routine MMR IHC on every sebaceous tumour (now increasingly recommended across all regions). In sun-rich regions (India, Australia), concurrent actinic damage and skin-cancer surveillance take on extra weight in the overall management plan. [1]

Exam Pearls

[1] [1]

Exam application bank (NEET-PG / INICET)

One-line answer

Sebaceous hyperplasia is a common, benign, age-related proliferation of mature sebaceous glands presenting as small (2–9 mm), soft, yellowish papules with a characteristic central dell (umbilication) on the face of middle-aged to older adults. Histology shows enlarged, mature sebaceous lobules arranged around a central dilated duct. The key clinical challenge is distinguishing it from nodular basal cell carcinoma (both are pearly papules on sun-exposed skin of older adults). Dermoscopy shows the pathognomonic crown vessels, yellow-white lobules (cumulus sign) and central umbilication (bonbon toffee sign). Treatment is cosmetic: cryotherapy, electrodessication, CO2 / Er:YAG / pulsed-dye laser, photodynamic therapy, or oral isotretinoin for extensive lesions. Multiple or atypical sebaceous tumours (adenoma, sebaceoma, sebaceous carcinoma) raise suspicion for Muir-Torre syndrome, a phenotyp

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Sebaceous hyperplasia.

[1]

References

1. [1]Hussein L, Perrett CM, et al. Treatment of sebaceous gland hyperplasia: a review of the literature J Dermatolog Treat, 2021.PMID 32011918
2. [2]Liu A, Taylor MB, Sotoodian B, et al. Treatment of Sebaceous Hyperplasia by Laser Modalities: A Review of the Literature and Presentation of Our Experience With Erbium-doped Yttrium Aluminium Garnet (Er:YAG) J Drugs Dermatol, 2020.PMID 32484621
3. [3]Zaballos P, Ara M, Puig S, Malvehy J. Dermoscopy of sebaceous hyperplasia Arch Dermatol, 2005.PMID 15967945
4. [4]Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study Arch Dermatol, 2004.PMID 15611426
5. [5]Oztas M, Ozdemir M, Arturk N. Bonbon toffee sign: a new dermatoscopic feature for sebaceous hyperplasia J Eur Acad Dermatol Venereol, 2008.PMID 18540985
6. [6]Bhaijee F, Pace MB, Xie J, et al. Muir-Torre syndrome Arch Pathol Lab Med, 2014.PMID 25427047
7. [7]Roberts ME, Riegert-Johnson DL, Lank NM, Thomas BC, Bronner MP. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome Genet Med, 2014.PMID 24603434
8. [8]Caytemel C, et al. Systemic isotretinoin treatment in a renal transplant patient developing sebaceous hyperplasia due to cyclosporine North Clin Istanb, 2020.PMID 33381706